JP2014511393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511393A5 JP2014511393A5 JP2013557763A JP2013557763A JP2014511393A5 JP 2014511393 A5 JP2014511393 A5 JP 2014511393A5 JP 2013557763 A JP2013557763 A JP 2013557763A JP 2013557763 A JP2013557763 A JP 2013557763A JP 2014511393 A5 JP2014511393 A5 JP 2014511393A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- effective amount
- therapeutically effective
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449716P | 2011-03-07 | 2011-03-07 | |
| US61/449,716 | 2011-03-07 | ||
| PCT/US2012/027368 WO2012121988A2 (en) | 2011-03-07 | 2012-03-02 | Methods for treating diseases using isoindoline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511393A JP2014511393A (ja) | 2014-05-15 |
| JP2014511393A5 true JP2014511393A5 (US20040106767A1-20040603-C00005.png) | 2015-04-16 |
Family
ID=45852726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557763A Pending JP2014511393A (ja) | 2011-03-07 | 2012-03-02 | イソインドリン化合物を用いた疾患の治療方法 |
Country Status (5)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015006051A2 (pt) * | 2012-10-11 | 2017-07-04 | Nerre Therapeutics Ltd | usos inéditos |
| EP3539539A1 (en) * | 2013-06-17 | 2019-09-18 | Celgene Corporation | Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| RU2538615C1 (ru) * | 2013-08-20 | 2015-01-10 | Общество с ограниченной ответственностью "УНИФАРМ" (ООО "УНИФАРМ"). | Средство для профилактики и лечения простатита и аденомы предстательной железы |
| CN105669478A (zh) * | 2014-11-17 | 2016-06-15 | 重庆医药工业研究院有限责任公司 | 一种制备3-氨基邻苯二甲酸及其衍生物的方法 |
| EP3236903B1 (en) | 2014-12-23 | 2021-04-21 | Intellectual Property Associates, LLC | Methods and formulations for transdermal administration |
| WO2017085568A1 (en) * | 2015-11-19 | 2017-05-26 | Alembic Pharmaceuticals Limited | An improved process and novel polymorphic form of apremilast |
| CN105388237B (zh) * | 2015-12-28 | 2017-02-01 | 成都百裕金阁莱药业有限公司 | 阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法 |
| WO2017168433A1 (en) * | 2016-03-30 | 2017-10-05 | Aizant Drug Research Solutions Private Limited | Apremilast pharmaceutical compositions |
| US20190374508A1 (en) | 2017-01-27 | 2019-12-12 | Sarudbhava Formulations Private Limited | Therapeutic topical compositions of apremilast |
| EP3681479B1 (en) | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| WO2020058992A1 (en) * | 2018-09-21 | 2020-03-26 | Sarudbhava Formulations Private Limited | Improved and stable apremilast pharmaceutical compositions |
| CA3125886A1 (en) * | 2019-01-11 | 2020-07-16 | Novartis Ag | Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa |
| WO2023120466A1 (ja) * | 2021-12-23 | 2023-06-29 | 沢井製薬株式会社 | アプレミラスト水和物含有製剤 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| CN101491520B (zh) * | 2002-05-28 | 2011-03-16 | 尼科梅德有限责任公司 | 局部应用的药物制剂 |
| EP2371859A3 (en) | 2002-07-19 | 2011-12-28 | Abbott Biotechnology Ltd | Treatment of TNF alpha related disorders |
| MXPA05003264A (es) | 2002-09-27 | 2005-10-18 | Johnson & Johnson | Pirroles 3,4-disustituidos y su uso en el tratamiento de enfermedades inflamatorias. |
| US20080267905A1 (en) * | 2004-05-05 | 2008-10-30 | Celgene Corporation | Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases |
| DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| JP2008523102A (ja) * | 2004-12-13 | 2008-07-03 | セルジーン・コーポレーション | Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用 |
| US20070155791A1 (en) | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| WO2008013791A2 (en) * | 2006-07-24 | 2008-01-31 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| EP2146989B1 (en) | 2007-04-16 | 2012-01-04 | Leo Pharma A/S | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
| MX2010010454A (es) * | 2008-03-27 | 2010-12-20 | Celgene Corp | Formas solidas que comprenden (+)-2-[1-(3-etoxi-4-metoxifenil)-2-m etilsulfoniletil]-4-acetilaminoisoindolina-1,3-diona, composiciones de la misma y usos de la misma. |
| SI2379548T1 (sl) * | 2008-12-19 | 2016-06-30 | Leo Pharma A/S | Triazolopiridini kot fosfodiesterazni inhibitorji za zdravljenje kožnih bolezni |
| JP5715070B2 (ja) * | 2009-02-16 | 2015-05-07 | ノグラ ファーマ リミテッド | アルキルアミド化合物およびその使用 |
| EP2448937B1 (en) | 2009-06-30 | 2014-04-09 | Piramal Enterprises Limited | Imidazo[4,5-c]quinoline derivatives and their use in the treatment of tumours and/or inflammations |
| MX337893B (es) | 2009-11-10 | 2016-03-28 | Celgene Corp | Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion. |
-
2012
- 2012-03-02 US US14/003,750 patent/US9387195B2/en active Active
- 2012-03-02 EP EP17208060.8A patent/EP3320902B1/en not_active Revoked
- 2012-03-02 ES ES17208060T patent/ES2868231T3/es active Active
- 2012-03-02 ES ES12709437T patent/ES2711100T3/es active Active
- 2012-03-02 WO PCT/US2012/027368 patent/WO2012121988A2/en active Application Filing
- 2012-03-02 EP EP12709437.3A patent/EP2683376B1/en active Active
- 2012-03-02 JP JP2013557763A patent/JP2014511393A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511393A5 (US20040106767A1-20040603-C00005.png) | ||
| JP2016540738A5 (US20040106767A1-20040603-C00005.png) | ||
| JP2014516942A5 (US20040106767A1-20040603-C00005.png) | ||
| JP2013155188A5 (US20040106767A1-20040603-C00005.png) | ||
| FI3865484T3 (fi) | Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon | |
| WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
| JP2012255026A5 (US20040106767A1-20040603-C00005.png) | ||
| AU2015288060A1 (en) | Treatment of leukemia with histone deacetylase inhibitors | |
| JP2012515184A5 (US20040106767A1-20040603-C00005.png) | ||
| JP2012517427A5 (US20040106767A1-20040603-C00005.png) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| HRP20211644T1 (hr) | Liječenje ili prevencija kardiovaskularnih događaja administracijom kolhicina | |
| JP2012193216A5 (US20040106767A1-20040603-C00005.png) | ||
| JP2013540766A5 (US20040106767A1-20040603-C00005.png) | ||
| JP2015515985A5 (US20040106767A1-20040603-C00005.png) | ||
| WO2015034678A3 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| JP2019530706A5 (US20040106767A1-20040603-C00005.png) | ||
| JP2015537009A5 (US20040106767A1-20040603-C00005.png) | ||
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
| WO2013022243A3 (ko) | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| FI3302451T3 (fi) | Palmitoyylietanoliamidia (pea) ja lykopeenia sisältävä yhdistelmä käytettäväksi inflammatoristen sairauksien hoidossa |
